Roche (RHHBY) and SeqWright Collaborate to Help Elucidate the Underlying Genetic Causes of Heart Disease
6/5/2009 9:45:07 AM
BRANFORD, Conn.--(BUSINESS WIRE)--Utilizing next generation sequencing and the latest advancements in sequence capture, SeqWright, a world-wide leader in custom genomic and molecular biology services, has announced a collaboration with Roche Applied Science and the University of Miami Miller School of Medicine. The research focuses on a major study to help identify possible genetic variants associated with dilated cardiomyopathy, a disease of heart muscle. In this collaboration SeqWright used NimbleGen Sequence Capture Human Exome Arrays to enrich over 180,000 exons from DNA samples from individuals affected with dilated cardiomyopathy. Using the Genome Sequencer FLX, a technology of 454 Life Sciences, SeqWright is sequencing the enriched exons to detect genetic variants within these samples, including single nucleotide polymorphisms (SNP’s) and insertions and deletions. The complete solution from Roche allows targeted re-sequencing of all of the coding exons, called the human exome, representing the portion of the human genome that is transcribed and translated into the myriad of proteins that function within all cells in the human body.
comments powered by